Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Vaxart’s effort to turn oral vaccine science into shareholder value isn’t simple—the company’s 10-K dives into recombinant vectors, phase 2 data and R&D spending shifts. If parsing hundreds of pages of biotech jargon feels daunting, Stock Titan’s AI distills every Vaxart SEC filing into clear, decision-ready insights.
Need the latest Vaxart quarterly earnings report 10-Q filing to gauge cash runway, a rapid alert when a new Vaxart 8-K material events explained hits EDGAR, or real-time Vaxart insider trading Form 4 transactions? Our platform delivers. AI summaries flag dilution risks, partnership revenue and clinical milestones, while smart search jumps straight to vaccine efficacy tables. You’ll also find:
- Vaxart annual report 10-K simplified for pipeline timelines and manufacturing strategy.
- Vaxart proxy statement executive compensation linking stock-based pay to trial progress.
- Vaxart Form 4 insider transactions real-time so you can monitor executives accumulating shares before data releases.
Investors often ask, “understanding Vaxart SEC documents with AI” or “Vaxart earnings report filing analysis.” Our answer: curated signals highlighting how tablet-based vaccines may disrupt injection-only markets, quarter-over-quarter cash flow trends, and material agreements with contract manufacturers. Skip the PDF hunt—let Stock Titan surface what matters, from GMP facility updates to executive stock transactions Form 4. Every filing, every footnote, explained simply so you act with confidence.
Vaxart, Inc. is offering and selling 11,111,111 shares of common stock at $0.45 per share in a privately negotiated transaction with Dynavax Technologies Corporation.
The company estimates net proceeds of approximately $5 million, to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. No underwriters or placement agents are involved. Delivery of shares is expected on or about November 6, 2025. Shares outstanding were 228,957,259 as of September 30, 2025, and are expected to be 240,069,844 immediately after the offering. Vaxart’s stock trades on the OTCQX under VXRT; the last reported price on November 3, 2025 was $0.33 per share.
Vaxart (VXRT) signed an exclusive, worldwide license and collaboration with Dynavax for its investigational oral coronavirus vaccines, including its oral COVID‑19 candidate. Vaxart will complete its ongoing Phase 2b trial and an end‑of‑Phase 2 FDA meeting; after that, Dynavax may elect to assume further development.
Dynavax will pay $25 million upfront and purchase 11,111,111 Vaxart shares at $0.45 per share (about $5 million) under Vaxart’s shelf registration, with closing expected on or about November 6, 2025. If Dynavax elects to take over development, it will pay an additional $50 million.
Vaxart may receive up to $195 million in regulatory milestones, up to $425 million in net sales milestones, and tiered royalties in the low‑to‑mid teens on net sales for licensed indications. Vaxart retains its platform rights for all non‑coronavirus indications. If Dynavax does not elect to continue, the agreement will terminate.
On
Vaxart, Inc. informed investors that a previously adjourned special meeting of stockholders, originally convened on
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
